甲胺作为一种治疗抗性血液性恶性瘤的治疗工具:文献综述
Graziele Silva Paz1, Janaina Fernandes1
1NUMPEX-BIO, Campus Santa Cruz da Serra, Federal Univesity of Rio de Janeiro, Duque de Caxias, Brazil.
Chinese clinical oncology
|June 11, 2024
概括
甲胺在治疗血液性恶性瘤 (HMs) 中表现有前途. 这种药物可以使HMs对治疗重新敏感并克服耐药性,改善患者的生存率和预后.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 血液性恶性瘤包括白血病,淋巴瘤和多发性骨髓瘤.
- 尽管治疗进展,但药物耐药性,复发和耐药性疾病的发病率正在增加.
- 迫切需要新的治疗策略来管理血液性恶性瘤.
研究的目的:
- 审查甲福明在血液性恶性瘤中的抗瘤作用机制.
- 总结最近关于甲福明在治疗HM的疗效的研究,包括耐药病例.
- 探索甲福明在克服药物耐药性和预防HMS复发方面的潜力.
主要方法:
- 对1996年至2023年间发表的研究的文献综述.
- 在PubMed和临床试验数据库 (clinicaltrials.gov) 中进行的搜索.
- 包括体外,体内和临床试验数据关于甲福尔的作用在HMs.
主要成果:
- 甲胺显示出作为抗HM药物的能力,使HM对常规药物重新敏感.
- 甲福明在克服复发性和耐药性血液性恶性瘤方面显示出潜力.
- 研究表明,甲福明对HMs的癌症干细胞 (CSCs) 有抑制作用.
结论:
- 甲福明是增强血液恶性瘤治疗反应的有希望的药物.
- 甲胺可以通过增强HM反应来改善患者的生存率和预后.
- 需要进一步探讨甲胺的作用,特别是关于CSC和耐药性.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K


